UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

June 07, 2022

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.

June 04, 2022

Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative breast cancer with endocrine therapy resistance, reducing the risk of disease progression by 34% vs standard chemotherapy, according to results of the phase 3 TROPiCS-02 trial.

May 03, 2022

Thomas Martin, MD, discusses updates from the CARTITUDE-1 trial, as well as the future of CARs and bispecific T cell engagers in multiple myeloma.

April 18, 2022

Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.

March 29, 2022

UCSF’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health.

March 23, 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

March 10, 2022

March 04, 2022

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

February 23, 2022

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

February 14, 2022

Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.

January 31, 2022

Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.

January 19, 2022

Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.

December 23, 2021

Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers ​to use throughout the therapeutic process.

December 14, 2021

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

November 26, 2021

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.

November 16, 2021

The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.

October 25, 2021

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

October 19, 2021

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

September 28, 2021

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

September 28, 2021

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.